首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >NUMBER NEEDED TO TREAT AND COST PER CLINICALLY MEANINGFUL OUTCOME OF ENZALUTAMIDE AND ABIRATERONE ACETATE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT FAILED ANDROGEN DEPRIVATION THERAPY IN BRAZIL

【24h】

NUMBER NEEDED TO TREAT AND COST PER CLINICALLY MEANINGFUL OUTCOME OF ENZALUTAMIDE AND ABIRATERONE ACETATE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT FAILED ANDROGEN DEPRIVATION THERAPY IN BRAZIL

机译：根据临床意义评估恩扎鲁米特和醋酸阿比特雷酮用于治疗转移性抗前列腺癌的前列腺癌的治疗和费用的数字

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2016年第7期|共1页
作者
Sasse A. P.; Lopes G.; Teich V; Fay A. P.; Abadi M.; Schultz N. M.; Stefani S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. NUMBER NEEDED TO TREAT AND COST PER CLINICALLY MEANINGFUL OUTCOME OF ENZALUTAMIDE AND ABIRATERONE ACETATE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT FAILED ANDROGEN DEPRIVATION THERAPY IN BRAZIL [J] . Sasse A. P., Lopes G., Teich V, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：根据临床意义评估恩扎鲁米特和醋酸阿比特雷酮用于治疗转移性抗前列腺癌的前列腺癌的治疗和费用的数字
2. NUMBER NEEDED TO TREAT AND ASSOCIATED INCREMENTAL COSTS OF TREATMENT WITH ENZALUTAMIDE VERSUS ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SPAIN AND THE UNITED KINGDOM [J] . Duran A., Watt M., Flanders S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：治疗和相关的烯醇胺治疗的醋酸盐和血液治疗中的化疗 - 幼稚患者的抗泼尼松治疗的数量，在西班牙和英国的转移阉割前列腺癌中
3. NUMBER NEEDED TO TREAT AND ASSOCIATED INCREMENTAL COSTS OF TREATMENT WITH ENZALUTAMIDE VERSUS ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SPAIN AND THE UNITED KINGDOM [J] . Duran A., Watt M., Flanders S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：治疗和相关的烯醇胺治疗的醋酸盐和血液治疗中的化疗 - 幼稚患者的抗泼尼松治疗的数量，在西班牙和英国的转移阉割前列腺癌中
4. Serum levels of sex hormones before and after androgen deprivation therapy in Japanese prostate cancer patients [C] . A. Komiya, K. Ichimatsu, A. Morii, International Congress of Andrology . 2009

机译：日本前列腺癌患者中雄激素剥夺治疗前后的性激素血清水平
5. Cost and Management of Fractures in Medicare Beneficiaries with Non-Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy. [D] . Yong, Candice Yuk Chen. 2015

机译：用雄激素剥夺疗法治疗的非转移性前列腺癌医疗保险受益人骨折的成本和管理。
6. Clinical outcomes of First-line Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Deprivation Therapy (ADT) + Docetaxel (D) or ADT alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [O] . Edoardo Francini, Steven Yip, Shubidito Ahmed, -1

机译：一线醋酸阿比特龙（AA）或恩扎鲁胺（E）用于雄激素剥夺疗法（ADT）+多西他赛（D）或仅ADT用于转移性激素敏感性前列腺癌（mHSPC）的转移性去势抵抗性前列腺癌（mCRPC）的临床结果
7. Cost Effectiveness of Abiraterone Acetate Plus Prednisone in the Pre-Chemotherapy Setting Followed by Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration-Resistant Prostate Cancer Patients Under the Brazilian Private Health Care System Perspective [O] . L Pititto, E Asano 2016

机译：AbiraTerone醋酸盐加上泼尼松在化疗预疗法中的成本有效性，然后在化疗后的依齐甲酰胺，与巴西私人医疗系统的转移阉割前列腺癌患者相反的治疗序列相反

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号